Claims
- 1. A compound having the structural formula (I)
- 2. The compound of claim 1, wherein R1, R2 and R3 are selected from the group consisting of hydrogen, hydroxyl, C1-C6 alkyl, halo, C1-C6 alkoxy, and C5-C12 aryloxy, and further wherein either R1 and R2, or R2 and R3, can be joined to form a two-atom or three-atom linkage selected from alkylene, substituted alkylene, and heteroalkylene;
R4 is selected from O, S, NH and CH2; R5 is selected from the group consisting of C6-C32 acyloxy and NH2; R6, R7, R8 and R9 are independently selected from the group consisting of hydrogen, C1-C6 alkyl, C1-C6 alkoxy, and C5-C12 aryloxy, or R6 and R7 are linked together to form a cyclohexyl, cyclopentyl, or phenyl ring, and R8 and R9 are hydrogen, or R8 and R9 are linked together to form a cyclohexyl, cyclopentyl, or phenyl ring, and R6 and R7 are hydrogen; and R10 and R11 are independently selected from the group consisting of hydrogen, hydroxyl, C1-C6 alkyl, C1-C6 alkoxy, and halo.
- 3. The compound of claim 2, wherein R4 is O.
- 4. The compound of claim 3, wherein R7, R9, R10 and R11 are hydrogen.
- 5. The compound of claim 4, in enantiomerically pure form in the 2β,3β-cis, 2α,3α-cis, 2α,3β-trans, or 2β,3α-trans configuration.
- 6. The compound of claim 4, comprising a racemic mixture of the 2α,3β-trans and 2β,3α-trans enantiomers.
- 7. The compound of claim 4, comprising a racemic mixture of the 2α,360 -cis and 2β,362 -cis enantiomers.
- 8. The compound of claim 4, wherein:
R5 is an acyloxy substituent having the structure 29in which R12, R13, and R14 are independently selected from the group consisting of hydrogen, hydroxyl, alkyl, alkoxy, and aryloxy.
- 9. The compound of claim 8, wherein:
R12, R13, and R14 are selected from the groups consisting of hydroxyl, C1-C6 alkyl, C1-C6 alkoxy, and C5-C12 aryloxy.
- 10. The compound of claim 9, wherein:
R12, R13, and R14 are independently selected from the group consisting of hydroxyl, methyl, and methoxy, and benzyloxy.
- 11. A compound having the structural formula (II)
- 12. The compound of claim 11, wherein R1, R2 and R3 are selected from the group consisting of hydroxyl, C1-C6 alkyl, halo, C1-C6 alkoxy, and C5-C12 aryloxy, and further wherein either R1 and R2, or R2 and R3, can be joined to form a two-atom or three-atom linkage selected from alkylene, substituted alkylene, and heteroalkylene; and
R6 and R8 are selected from the group consisting of hydrogen, C1-C6 alkyl, C1-C6 alkoxy, and C5-C12 aryloxy.
- 13. The compound of claim 12, wherein R1, R2, and R3 are independently selected from hydroxyl, methyl, and methoxy; and
R6, and R8 are independently selected from hydrogen, hydroxyl, methyl, and methoxy.
- 14. An analog of (−)-epigallocatechin-3-gallate (EGCG), wherein the analog contains at least one modification relative to ECGC that results in an IC50 of less than 60 when the analog is evaluated for its ability to inhibit growth in a breast cancer cell line using MTT assay.
- 15. The analog of claim 14, wherein the analog contains at least one modification relative to ECGC that results in an IC50 of less than 25 when the analog is evaluated for its ability to inhibit growth in a breast cancer cell line using MTT assay.
- 16. The analog of claim 15, wherein the analog contains at least one modification relative to ECGC that results in an IC50 of less than 15 when the analog is evaluated for its ability to inhibit growth in a breast cancer cell line using MTT assay.
- 17. A compound having the structural formula selected from
- 18. A pharmaceutical composition comprising a therapeutically effective amount of the compound of claim 1 in combination with a pharmaceutically acceptable carrier.
- 19. A pharmaceutical composition comprising a therapeutically effective amount of the compound of claim 3 in combination with a pharmaceutically acceptable carrier.
- 20. A pharmaceutical composition comprising a therapeutically effective amount of the compound of claim 4 in combination with a pharmaceutically acceptable carrier.
- 21. A pharmaceutical composition comprising a therapeutically effective amount of the compound of claim 5 in combination with a pharmaceutically acceptable carrier.
- 22. A pharmaceutical composition comprising a therapeutically effective amount of the compound of claim 6 in combination with a pharmaceutically acceptable carrier.
- 23. A pharmaceutical composition comprising a therapeutically effective amount of the compound of claim 8 in combination with a pharmaceutically acceptable carrier.
- 24. A pharmaceutical composition comprising a therapeutically effective amount of the compound of claim 9 in combination with a pharmaceutically acceptable carrier.
- 25. A pharmaceutical composition comprising a therapeutically effective amount of the compound of claim 15 in combination with a pharmaceutically acceptable carrier.
- 26. The composition of any one of claims 18 through 25, wherein the pharmaceutically acceptable carrier is suitable for oral administration and the composition comprises an oral dosage form.
- 27. The composition of claim 26, wherein the oral dosage form is a tablet.
- 28. The composition of claim 26, wherein the oral dosage form is a capsule.
- 29. The composition of any one of claims 18 through 25, wherein the pharmaceutically acceptable carrier is suitable for parenteral administration and the composition comprises a parenterally administrable formulation.
- 30. A method for treating a patient suffering from cancer, comprising administering to the individual a therapeutically effective amount of the compound of claim 1.
- 31. A method for treating a patient suffering from cancer, comprising administering to the individual a therapeutically effective amount of the compound of claim 3.
- 32. A method for treating a patient suffering from cancer, comprising administering to the individual a therapeutically effective amount of the compound of claim 4.
- 33. A method for treating a patient suffering from cancer, comprising administering to the individual a therapeutically effective amount of the compound of claim 5.
- 34. A method for treating a patient suffering from cancer, comprising administering to the individual a therapeutically effective amount of the compound of claim 6.
- 35. A method for treating a patient suffering from cancer, comprising administering to the individual a therapeutically effective amount of the compound of claim 8.
- 36. A method for treating a patient suffering from cancer, comprising administering to the individual a therapeutically effective amount of the compound of claim 9.
- 37. A method for treating a patient suffering from cancer, comprising administering to the individual a therapeutically effective amount of the compound of claim 15.
- 38. The method of any one of claims 30 through 37, wherein the cancer is prostate cancer, uterine cancer, or breast cancer.
- 39. The method of claim 38, wherein the cancer is breast cancer.
- 40. A chemopreventive method comprising administering a prophylactically effective amount of the compound of claim 1 to a patient susceptible to developing cancer.
- 41. A chemopreventive method comprising administering a prophylactically effective amount of the compound of claim 3 to a patient susceptible to developing cancer.
- 42. A chemopreventive method comprising administering a prophylactically effective amount of the compound of claim 4 to a patient susceptible to developing cancer.
- 43. A chemopreventive method comprising administering a prophylactically effective amount of the compound of claim 5 to a patient susceptible to developing cancer.
- 44. A chemopreventive method comprising administering a prophylactically effective amount of the compound of claim 6 to a patient susceptible to developing cancer.
- 45. A chemopreventive method comprising administering a prophylactically effective amount of the compound of claim 8 to a patient susceptible to developing cancer.
- 46. A chemopreventive method comprising administering a prophylactically effective amount of the compound of claim 9 to a patient susceptible to developing cancer.
- 47. A chemopreventive method comprising administering a prophylactically effective amount of the compound of claim 15 to a patient susceptible to developing cancer.
Parent Case Info
[0001] CROSS-REFERENCE TO RELATED APPLICATIONS
[0002] This application is a continuation-in-part of application Ser. No. 10/313,968, filed Dec. 6, 2002, which is incorporated by reference in its entirety.
Continuation in Parts (1)
|
Number |
Date |
Country |
Parent |
10313968 |
Dec 2002 |
US |
Child |
10731690 |
Dec 2003 |
US |